Most Read Articles
Stephen Padilla, 4 days ago
Use of noninvasive ventilation (NIV), similar to invasive mechanical ventilation (IMV), appears to lessen mortality but may increase the risk for transmission of the novel coronavirus disease (COVID-19) in healthcare workers, suggest the results of a study.
Roshini Claire Anthony, 08 May 2020

At present, there are no definitive treatments for COVID-19. More than 300 clinical trials are ongoing in the search for a cure. Some of the treatments being tested were previously used, with varying levels of efficacy, in the treatment of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS).

Pank Jit Sin, 21 May 2020

Persons suffering from asthma should pay particular attention to SARS-CoV-2 precautionary measures such as social distancing, regular handwashing, and wearing of masks on top of keeping their asthma in control. This is because data collected so far paints a bleaker picture for asthmatics than the normal population should they catch COVID-19.

Pank Jit Sin, 21 May 2020
Two new studies have brought into question the widespread use of hydroxychloroquine in COVID-19 patients. One is French in origin while the other is Chinese.

Low BMI, high PaCO2 predict 90-day mortality in severe COPD

27 Jul 2019

High partial pressure of carbon dioxide (PaCO2) and age, low body mass index (BMI), and previous admission for exacerbations of chronic obstructive pulmonary disease (ECOPD) in the last 2 years strongly predict 90-day mortality in patients with severe COPD, according to the Classification and Regression Tree (CART) analysis of a recent study.

“In absence of any of these factors, no patients died, suggesting that this model indeed enables risk stratification,” the authors said.

In total, 364 hospitalized patients (mean age, 70.5 years; 54.4 percent male; mean forced expiratory volume in 1 s [FEV1], 45.2 percent of predicted) were included in the analysis. The rate of in-hospital mortality was 8.5 percent and 90-day mortality 16.2 percent.

The following factors independently predicted 90-day mortality: PaCO2 (odds ratio [OR], 1.31, 95 percent CI, 1.00–0.35), age (OR, 1.09, 0.06–0.11), BMI <18.5 kg/m2 (OR, 2.72, 0.53–1.47) and previous admission for ECOPD in the last 2 years (OR, 1.29, –0.14 to –0.65). According to the CART model, the most discriminatory factors were PaCO2 ≥9.1 kPa, age >80 years, BMI <18.5 kg/m2 and previous admission for ECOPD.

“ECOPD [is] associated with increased in‐hospital and short‐term mortality,” the authors said. “Developing an easy‐to‐use model to predict adverse outcomes will be useful in daily clinical practice and will facilitate management decisions.”

This retrospective, observational, cohort study enrolled all patients with ECOPD admitted to Maastricht University Medical Center between June 2011 and December 2014. The authors considered the last admission and recorded its demographic, clinical and biochemical data.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 4 days ago
Use of noninvasive ventilation (NIV), similar to invasive mechanical ventilation (IMV), appears to lessen mortality but may increase the risk for transmission of the novel coronavirus disease (COVID-19) in healthcare workers, suggest the results of a study.
Roshini Claire Anthony, 08 May 2020

At present, there are no definitive treatments for COVID-19. More than 300 clinical trials are ongoing in the search for a cure. Some of the treatments being tested were previously used, with varying levels of efficacy, in the treatment of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS).

Pank Jit Sin, 21 May 2020

Persons suffering from asthma should pay particular attention to SARS-CoV-2 precautionary measures such as social distancing, regular handwashing, and wearing of masks on top of keeping their asthma in control. This is because data collected so far paints a bleaker picture for asthmatics than the normal population should they catch COVID-19.

Pank Jit Sin, 21 May 2020
Two new studies have brought into question the widespread use of hydroxychloroquine in COVID-19 patients. One is French in origin while the other is Chinese.